
News|Articles|August 1, 2005
Dual peroxisome proliferator-activated receptor agonist demonstrates significant lipid benefits
Phase 3 clinical trial results have demonstrated that the dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist muraglitazar achieves significant beneficial lipid effects compared with pioglitazone, and the agent also provides long-term glycemic control in type 2 diabetics. The results were reported during the American Diabetes Association (ADA) 65th Annual Meeting in San Diego, Calif.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























